ad 5

AD 5 is a bioactive chemical.

Zaptuzumab (AD5-10) is a humanized monoclonal antibody targeting death receptor 5 (DR5) with high selective binding affinity. It specifically induces cancer cell death through caspase-mediated apoptosis and autophagic cell death (ACD). Zaptuzumab can activate antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Additionally, it induces reactive oxygen species (ROS) production and reduces glutathione (GSH) levels. In various xenograft mouse tumor models, Zaptuzumab has demonstrated significant tumor growth inhibition and favorable safety profiles.

Multitarget AD-IN-5 (Compound 20), a derivative of 9-Aminoacridine, is a neuroprotective agent. It exhibits IC50 values of 0.614 μM for hAChE, 0.448 μM for hBChE, 3.73 μM for MAO-A, and 1.55 μM for hMAO-B. This compound can reduce both the length and diameter of Aβ42 fibrils and decrease the number of fibrils per unit area. The CC50 value for SH-SY5Y cells is 95 μM. Multitarget AD-IN-5 is applicable in Alzheimer's disease research.

AD-5467 is a bioactive chemical.

D-I03 is a selective RAD52 inhibitor with a Kd of 25.8 µM. D-I03 inhibits RAD52-dependent single-strand annealing (SSA) and D-loop formation, with IC₅₀ values of 5 µM and 8 µM, respectively. D-I03 exerts significant growth inhibition on BRCA1/2-deficient cancer cells but has no effect on RAD51. D-I03 can be used in combination therapy studies for tumors with DNA damage repair defects.

NSC103054 is an A-ring dibrominated derivative of 17β-estradiol and acts as an inhibitor of ABCG2 transporter function (IC50=20–30 μM). NSC103054 modulates ABCG2/BCRP transporters by inhibiting ABCG2 activity and can be used in breast cancer research.

AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.

Blonanserin-D5 is a deuterium-labeled Blonanserin. Blonanserin (T1180) (AD-5423) is a dopamine D2/5-HT2 receptor antagonist with an atypical antipsychotic effect.

Blonanserin-D8 is a deuterium-labeled Blonanserin. Blonanserin (T1180) (AD-5423) is a dopamine D2/5-HT2 receptor antagonist with an atypical antipsychotic effect.

Blonanserin (AD-5423) is an atypical antipsychotic approved in Japan in January, 2008. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.

IBR2 (Isoquinoline) is a potent and specific RAD51 inhibitor known for its ability to suppress RAD51-mediated DNA double-strand break repair. By interfering with RAD51 multimerization, accelerating proteasome-mediated RAD51 protein degradation, inhibiting cancer cell growth, and inducing apoptosis, IBR2 has proved to be an effective compound in these aspects.

Blonanserin is an antagonist of dopamine-D2 and serotonin-S2.

Emzadirib (RAD51-IN-2) is a potent inhibitor of RAD51, showing potential anticancer activity and useful for studying DNA damage repair.

Kartogenin (KGN) is an activator of the smad4/smad5 pathway, and promotes the selective differentiation of multipotent mesenchymal stem cells into chondrocytes.

PSMA-D5 exhibits a binding affinity for PSMA with a Ki of 0.21 nM and becomes useful for PSMA tracing following radiolabeling. When marked with [68Ga], PSMA-D5 contains a DOTA chelator, facilitating the convenient labeling with therapeutic radionuclides such as 177Lu and 225Ac. Additionally, [68Ga]-labeled PSMA-D5 demonstrates exceptional pharmacokinetic properties and significant tumor uptake in 22Rv1 tumors. This compound can be employed in the synthesis and research of radiolabeled conjugates (RDC).

RAD51-IN-9 (Compound 3a) is an inhibitor of RAD51, specifically blocking its binding to ssDNA, with an IC50 of 17.85 μM. The compound has an LD50 of 40.21 μM in HEK293 cells and can sensitize cells to mitomycin C.

BRCA2-RAD51-IN-2 (compound S-35d) is a BRCA2-RAD51 inhibitor that, when combined with 10 µM Olaparib, can inhibit homologous recombination repair.

AD57, as polypharmacological cancer therapeutic, is designed to regulate multiple targets related to cancer blocks the receptor tyrosine kinase RET in Drosophila (IC50: 2 nM). AD57 effectively suppresses tyrosine kinase RET, weakens the activity of numero

RI-1 (RAD51 inhibitor 1) is a RAD51 inhibitor (IC50: 5-30 μM).

Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.

RI-2 is an optimized RAD51 inhibitor with an IC50 of 44.17 μM in the standard DNA binding assay; specifically inhibits HR(Homologous recombination) repair in human cells.

6-Hydroxy-DOPA is an allosteric inhibitor of RAD52, it inhibits proliferation of BRCA-deficient cancer cells in vitro and also inhibits APE1.

AD5075 is a bioactive chemical.

CAY10760 is a novel RAD51-BRCA2 protein–protein interaction inhibitor (EC₅₀ = 19 μM) that interferes with the homologous recombination process.